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As US health-care expenditures continue to spiral
upward, the value of this spending is increasingly ques-
tioned. General Motors (GM), once the leading man-
ufacturer and the largest private employer in the
United States, is nearly bankrupt, in large part because
it spends $1500 in health-care costs per vehicle,
whereas Toyota, which will shortly overtake GM in
global auto production, pays only $201 per vehicle for
health care in North America and $97 in Japan [1].
Although health-care costs are easy to measure as tan-
gible taxes or paycheck deductions, health-care bene-
ﬁts are much harder to evaluate and quantify. The
drivers of health-care cost increases are complex [2,3],
but to develop appropriate policies to constrain or
reorganize health-care spending, it is critically impor-
tant to properly compare health-care costs with health-
care value.
In this issue of Value in Health, Luce et al. [4]
provide  a  multifaceted  assessment  of  the  US  return
on investment for health-care expenditures, using three
independent methodological approaches. Using
(appropriately updated) societal life-year values of
$99,000 to $173,000, and conservatively considering
only the health care-related improvements in survival
over past two decades, they ﬁnd that a dollar of US
health-care spending generates between $1.55 and
$1.94 in overall health-care gains. Had they included
the reductions in morbidity and improvements in
employee productivity resulting from these expendi-
tures, the returns on investment would have been even
higher, but such gains are much more difﬁcult to quan-
tify than the survival improvements. When Luce et al.
look at certain disease-speciﬁc results in the Medicare
program and at the broader cost-effectiveness litera-
ture, they corroborate their overall average estimates
of return on investment with an impressive and inde-
pendent diversity of additional positive ﬁndings.
The Luce et al. study [4] is merely the latest in a
series of consistent ﬁndings by several health econo-
mists demonstrating the substantial positive social
value for aggregate US health-care spending [5–8]. The
logic behind these robust ﬁndings is easily sketched
out. Between 1980 and 2000, average US life expect-
ancy at birth increased by 3.2 years. A substantial
portion of this increased life expectancy should be
attributed to increased health-care spending (Luce et
al. [4], estimate 66.5% × 3.2 years = 2.13 years aver-
age survival gain) because medical care was the main
factor that changed during this time period. Multi-
plying the 2.13 years medical care survival gain times
the $100,000 to $173,000 life-year value times the
number of people surviving in 2000 who would have
died if 1980s medical care were still being used
(312,720) generates a societal savings calculation in
excess of $1 trillion because of increased medical care
spending.
Murphy and Topel [6] have used similar calcula-
tions to show that a medical technology, innovation,
preventive service, or treatment that could reduce can-
cer death rates by 1% would save the United States
approximately $400 to $500 billion, with similar esti-
mates for heart disease mortality reductions. Because it
is quite plausible that US pharmaceutical industry
R&D or National Institutes of Health (NIH) biomed-
ical research budget, each of which is roughly $40 bil-
lion annually could feasibly reduce either heart disease
or cancer death rates by 1% through a focused
research effort costing less than a single year’s R&D
expenditures, the societal returns to such biomedical
research are potentially greater than 10 to 1.
The importance of this ﬁnding cannot be overstated
as we grapple with the tax and payroll burdens of
increasing medical care costs. Many countries and
health-care systems, particularly outside the United
States, have successfully cut their growth rates for
health-care spending and biomedical research. But
health care is a productive sector of the economy, not
just a cost to employers and governments. Certainly,
increasing health-care costs make some employment
sectors and manufactured products, like automobiles,
less competitive, but the health-care sector itself is one
of the most robust areas of the economy for generating
new employment. The US Bureau of Labor Statistics
projects 4.4 million new health care-related jobs by
2012 [9].
The US NIH is unmatched anywhere else in the
world in terms of governmental commitment to bio-
medical R&D (see Fig. 1), and in the tangible beneﬁts
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produced by this research, including new understand-
ing and treatments for HIV/AIDS, cancer, heart dis-
ease, and nearly every other human malady. Similarly,
the United States spends more per capita on pharma-
ceutical R&D than Europe or Japan, reversing pat-
terns of the early 1990s (see Fig. 2). US pharmaceutical
and biotech exports also lead the world [10]. It is often
suggested that European and other economies that
free-ride on US biomedical R&D obtain nearly all of
the beneﬁts of US medical technology at much lower
health-care costs per capita. But being the ﬁrst to adopt
any new technology will always be more expensive
than waiting to adopt mature technologies. Europe
currently spends less than 60% of the United States on
pharmaceutical R&D per capita and invents only
about half as many new drugs.
According to a Bain Consultants study [11], Ger-
many saved $19 billion because it spent much less per
head than the United States on drugs in 2002. Never-
theless, Germany lost out on $4 billion from R&D,
patents and related beneﬁts that went elsewhere, $8
billion because high-value jobs went elsewhere, and $3
billion in proﬁt had German pharmaceutical manufac-
turers kept pace with rivals elsewhere. A further $2
billion was lost as the country shed corporate
headquarter positions. The cost of poorer-than-
necessary German health was $5 billion. In sum, Ger-
many’s $19 billion saving was in fact a $3 billion net
economic loss. According to the study coauthor
“When you add up all of the costs, the free rider model
is actually quite expensive.”
A strong argument can be made that the major
global health-care ﬁnancing problem is not that the
United States spends too much on health care, but
rather that every other country in the world spends
too little, particularly on biomedical R&D. Unques-
tionably, there is waste, inefﬁciency and harmful med-
ical interventions within the US health-care sector
[12]. A primary focus of health economics and out-
comes research is to identify and reduce these negative
aspects as far as possible. But as employers and poli-
ticians increasingly rush to the health-care cost cutting
bandwagons it is crucial that we recognize that these
costs are associated with enormous economic and
societal beneﬁts. The beneﬁts of biomedical R&D
accrue not only to this generation but to all future
generations. Once the magnitude of these beneﬁts is
understood, it is only logical that we should work to
Figure 2 Pharmaceutical R&D expenditure in
Europe, USA, and Japan from 1990 to 2003. n.a, not
available. Source: EFPIA member associations,
PhRMA, JPMA, Data 2003: estimate EFPIA & PhRMA
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Figure 1 Health-care R&D in government budgets as a percentage of
gross domestic product, 2002. n.a., not available. Source: Organization for
Economic Cooperation and Development (OECD) R&D Database, 2003.
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protect them from blunt and simplistic cost-cutting
measures.
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